| 摘要: |
| 目的：研究强心安神方对阿霉素性慢性心力衰竭大鼠N末端前体脑利钠肽（NT-proBNP）及葡萄糖调节蛋白78（GRP78）mRNA、CCAAT/增强子结合蛋白（CHOP） mRNA的影响,探讨该方的作用机制。方法：将Wistar大鼠分为正常对照组、模型组、卡托普利组及强心安神方大、小剂量组,每组15只,对除正常对照组外的其余组大鼠采用腹腔注射阿霉素法制备慢性心力衰竭模型,予药物干预4周,检测各组大鼠心衰指标NT-proBNP及内质网应激信号分子GRP78 mRNA、CHOP mRNA的表达。结果：强心安神方大、小剂量组NT-proBNP水平、GRP78 mRNA及CHOP mRNA表达均低于模型组,差异有统计学意义（P<0.05或P<0.01）,3项指标与卡托普利组比较,差异无统计学意义（P>0.05）;强心安神方大、小剂量组组内比较,大剂量组NT-proBNP水平及GRP78 mRNA表达均低于小剂量组,差异有统计学意义（P<0.05）,CHOP mRNA表达差异无统计学意义（P>0.05）。结论：强心安神方可降低内质网应激信号分子GRP78 mRNA、CHOP mRNA的表达,减轻心肌细胞损伤,从而保护心肌,抑制心肌重构。 |
| 关键词: 慢性心力衰竭 强心安神方 内质网应激 NT-proBNP GRP78 mRNA CHOP mRNA |
| DOI： |
|
|
| Effect of Qiangxin Anshen prescription on N-terminal pro-brain natriuretic peptide,glucose-regulated protein 78 mRNA,and CCAAT/enhancer-binding protein homologous protein mRNA in rats with chronic heart failure |
| WANG Fangting,LI Ru,QING Yuanyuan |
| (Hunan University of Chinese Medicine,Changsha 410208,Hunan,China;The Affiliated Hospital of Hunan Academy of Chinese Medicine,Changsha 410006,Hunan,China) |
| Abstract: |
| Objective：To investigate the effect of Qiangxin Anshen prescription on N-terminal pro-brain natriuretic peptide (NT-proBNP),glucose-regulated protein 78 (GRP78) mRNA,and CCAAT/enhancer-binding protein homologous protein (CHOP) mRNA in rats with chronic heart failure,as well as the mechanism of action of this prescription.Methods：Wistar rats were divided into normal control group,model group,captopril group,and high- and low-dose Qiangxin Anshen prescription groups.All rats except those in the normal control group were given intraperitoneal injection of adriamycin to establish a model of chronic heart failure,and after 4 weeks of drug intervention,the heart failure indicator NT-proBNP and the mRNA expression of GRP78 and CHOP were measured for each group.Results：Compared with the model group,the high- and low-dose Qiangxin Anshen prescription groups had significantly lower NT-proBNP level and mRNA expression levels of GRP78 and CHOP (P<0.05 or P<0.01),and there were no significant differences in these indicators between the high- and low-dose Qiangxin Anshen prescription groups and the captopril group (P>0.05).The high-dose Qiangxin Anshen prescription group had significantly lower NT-proBNP level and mRNA expression level of GRP78 than the low-dose Qiangxin Anshen prescription group (P<0.05),while there was no significant difference in the mRNA expression of CHOP between the two groups (P>0.05).Conclusion：Qiangxin Anshen prescription can reduce the mRNA expression of the endoplasmic reticulum stress signaling molecules GRP78 and CHOP and alleviate cardiomyocyte injury,thereby protecting the myocardium and inhibiting myocardial remodeling. |
| Key words: chronic heart failure Qiangxin Anshen prescription endoplasmil reticulum stress N-terminal pro-brain natriuretic peptide glucose-regulated protein 78 mRNA CCAAT/enhancer-binding protein homologous protein mRNA |
